News & Updates

Chemotherapy plus ICI treatment ups VTE risk in cancer patients
Chemotherapy plus ICI treatment ups VTE risk in cancer patients
27 Mar 2023

Combination treatment with immune checkpoint inhibitors (ICI) and chemotherapy is associated with a higher risk of venous thromboembolic events (VTE) in adult cancer patients, reveals a study. In addition, a similar VTE disease course is seen after ICI exposure, irrespective of other immune-related adverse events (irAEs).

Chemotherapy plus ICI treatment ups VTE risk in cancer patients
27 Mar 2023
Oral, on-the-skin immunotherapies show promise against peanut allergy in children
Oral, on-the-skin immunotherapies show promise against peanut allergy in children
27 Mar 2023 byStephen Padilla

Children who are allergic to peanuts may benefit from two immunotherapies, one oral and another epicutaneous or on-the-skin, which have demonstrated safety and efficacy in separate studies presented at the recent AAAAI 2023.

Oral, on-the-skin immunotherapies show promise against peanut allergy in children
27 Mar 2023
Polysaccharide hemostatic powder shows promise for peptic ulcer bleeding
Polysaccharide hemostatic powder shows promise for peptic ulcer bleeding
27 Mar 2023

In the initial endoscopic treatment of peptic ulcer bleeding, the use of polysaccharide hemostatic powder appears to be not less efficacious than conventional treatment, according to a study.

Polysaccharide hemostatic powder shows promise for peptic ulcer bleeding
27 Mar 2023
CAB+RPV LA vs B/FTC/TAF for HIV: Which is better?
CAB+RPV LA vs B/FTC/TAF for HIV: Which is better?
27 Mar 2023 byAudrey Abella

In virologically suppressed adults with HIV, the cabotegravir + rilpivirine long-acting (CAB+RPV LA) regimen was on par with bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) in terms of virologic efficacy, but the former gained the upper hand over the latter in terms of patient satisfaction and preference, the SOLAR* study reports.

CAB+RPV LA vs B/FTC/TAF for HIV: Which is better?
27 Mar 2023